Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Reuters briefs says Foundayo (orforglipron) 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1c reduction versus oral semaglutide 25 mg at 52 weeks in an indirect treatment comparison (Achieve-3).
Lilly says Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison.